Anzeige
Meldung des Tages: Der Vorteil des Meeresbodens: Wie Tiefsee-Knollen den landbasierten Bergbau übertreffen könnten

Nektar Therapeutics News

Aktie
WKN:  A419UB ISIN:  US6402683063 US-Symbol:  NKTR Branche:  Biotechnologie Land:  USA
72,00 €
+1,00 €
+1,41%
15:47:18 Uhr
Depot/Watchlist
Marktkapitalisierung *
7,03 Mrd. €
Streubesitz
27,94%
KGV
-5,04
Index-Zuordnung
-

Nektar Therapeutics News

19.03.26 - PR Newswire
NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Failing Clinical Enrollment Standards: SueWallSt
NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Failing Clinical Enrollment Standards ...
18.03.26 - PR Newswire
NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Failing Clinical Enrollment Standards: Levi & Korsinsky
NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Failing Clinical Enrollment Standards ...
17.03.26 - PR Newswire
NKTR Shareholder Alert: May 5, 2026 Lead Plaintiff Deadline in Nektar Therapeutics Securities Class Action Lawsuit -- The Gross Law Firm
NKTR Shareholder Alert: May 5, 2026 Lead Plaintiff Deadline in Nektar Therapeutics Securities Class Action Lawsuit -- The Gross Law Firm PR Newswire
16.03.26 - PR Newswire
NKTR INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026
NKTR INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026 PR Newswire
16.03.26 - PR Newswire
Nektar Therapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - NKTR
Nektar Therapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - NKTR PR Newswire
15.03.26 - PR Newswire
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit PR Newswire
12.03.26 - PR Newswire
Nektar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
Nektar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results PR Newswire
12.03.26 - PR Newswire
Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain Officers - NKTR
Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain Officers - NKTR PR Newswire
12.03.26 - PR Newswire
NKTR INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026
NKTR INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026 PR Newswire
09.03.26 - PR Newswire
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit PR Newswire
09.03.26 - PR Newswire
NKTR Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Securities Class Action Against Nektar Therapeutics
NKTR Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Securities Class Action Against Nektar Therapeutics PR Newswire
06.03.26 - PR Newswire
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
26.02.26 - PR Newswire
Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2025 on Thursday, March 12, 2026, After Close of U.S.-Based Financial Markets
Nektar to Announce Financial Results for the Fourth Quarter and Year-​Ended 2025 on Thursday, March 12, 2026, After Close of U.S.-Based Financial Markets PR Newswire
24.02.26 - PR Newswire
Nektar Therapeutics to Participate in Two Investor Conferences in March
Nektar Therapeutics to Participate in Two Investor Conferences in March PR Newswire
17.02.26 - PR Newswire
Nektar Therapeutics Announces Research Collaboration with UCSF and Dr. Stephen Hauser for NKTR-0165, a Tumor Necrosis Factor Receptor 2 (TNFR2) Antibody, in Multiple Sclerosis
Nektar Therapeutics Announces Research Collaboration with UCSF and Dr. Stephen Hauser for NKTR-0165, a Tumor Necrosis Factor Receptor 2 (TNFR2) Antibody, in Multiple ...
13.02.26 - PR Newswire
Nektar Therapeutics Announces Closing of $460 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Nektar Therapeutics Announces Closing of $460 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares PR Newswire
11.02.26 - PR Newswire
Nektar Therapeutics Announces Pricing of Upsized $400 Million Public Offering
Nektar Therapeutics Announces Pricing of Upsized $400 Million Public Offering PR Newswire
10.02.26 - PR Newswire
Nektar Therapeutics Announces Proposed Public Offering
Nektar Therapeutics Announces Proposed Public Offering PR Newswire
10.02.26 - PR Newswire
New REZOLVE-AD Maintenance Data in Atopic Dermatitis Demonstrate Rezpegaldesleukin Resulted in Durable and New Responses Across Key Disease Measurements with Both Monthly and Quarterly Dosing
New REZOLVE-​AD Maintenance Data in Atopic Dermatitis Demonstrate Rezpegaldesleukin Resulted in Durable and New Responses Across Key Disease Measurements with ...
09.02.26 - PR Newswire
Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Maintenance Period for its REZOLVE-AD Phase 2b Study of Rezpegaldesleukin in Atopic Dermatitis on February 10, 2026
Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Maintenance Period for its REZOLVE-​AD Phase 2b Study of Rezpegaldesleukin in Atopic Dermatitis on ...

Newssuche

Videos

newspaper
16.04.26 +0,31%
Technical Trading: Treffsichere Signale für Gold
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »